Kinnate Biopharma Inc.
kinnate.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Mar 28, 2024. Its latest SEC filing is a SC 13G/A from Nov 13, 2024.
10-K for FY2023, filed Mar 28, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops targeted drug candidates for hard-to-treat cancers tied to specific genetic changes.
10-K for FY2023, filed Mar 28, 2024We are a clinical-stage precision oncology company that has focused on the discovery, design and development of small molecule kinase…View ↗
How Were They Changing?
-
Apr 3, 2024
XOMA completed its acquisition of Kinnate
Kinnate became a wholly owned subsidiary of XOMA after the tender offer and merger closed.
Sources
8-K, filed Apr 3, 2024
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on April 3, 2024, Merger Sub completed a tender…View ↗
Loading...
